Work

970 Allogeneic Genetically-modified Tumor Cell Vaccine (rcc-26/cd80/il-2) in Patients With Metastatic Renal Cell Carcinoma - a Phase I Trial

Year: 2007

Type: conference-abstract

Source: European Urology Supplements

DOI: 10.1016/s1569-9056(07)60965-8

Authors: A. Buchner, H. Pohla, A. Baur, J. Kopp, A. Pezzutto, T. Blankenstein, D. Schendel, C. Stief, A. Hofstetter, R. Oberneder

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2017673039

Cites:

Cited by: 1

Related to: 10